

Innovation in Breast Cancer

iBC 2024

15th • 16th Feb
2024
VIRTUAL FORMAT



Sara Hurvitz

University of Washington, Fred Hutchinson Cancer Center, Seattle, USA

Dr. Sara Hurvitz is a medical oncologist and clinical research leader who is senior vice president of the Clinical Research Division at Fred Hutch and head of the Division of Hematology and Oncology at the University of Washington Department of Medicine. A graduate of the Keck School of Medicine at the University of Southern California, Hurvitz is an international expert in breast oncology and a leader in clinical and laboratory-based oncology research, with extensive experience leading clinical trials in all phases. Dr. Hurvitz works to boost the national reputation of the solid tumor clinical research program and oversees the continued growth of clinical research programs in stem cell transplantation and cell therapy, hematologic cancers and nonmalignant hematology. Dr. Hurvitz has contributed extensively to the growth of clinical research programs since joining the University of California, Los Angeles as a resident in 1999. She is a member of the American College of Physicians, the American Society of Hematology, the American Society of Clinical Oncology, American Association for Cancer Research, the European Society of Medical Oncology and the American College of Physicians.

Other Appointments & Affiliations

Professor and Head, Division of Hematology and Oncology
Department of Medicine, University of Washington School of Medicine

Education

University of California, Los Angeles, Hematology/Oncology Fellowship, completed 2006
University of California, Los Angeles, Internal Medicine Internship and Residency, completed 2002
University of Southern California, 1999, MD
University of California, Irvine, 1993, BS (Biology), BA (Psychology)

Research Interests

Preclinical evaluation of novel targeted therapeutics for breast cancer
Development of first-in-human phase I clinical trials of new cancer therapies
Phase II-III clinical trials for breast cancer
Triple negative breast cancer
HER2+ breast cancer
HER2-low breast cancer
Hormone receptor positive breast cancer
Targeted therapies for breast cancer

Clinical Expertise

Medical (medicinal) oncology management of breast cancer including early stage and late stage disease, neoadjuvant treatments, novel targeted therapies against HER2, estrogen receptor positive and triple negative breast cancer. Immune based treatments for breast cancer.